Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

Statements of Changes in Equity

(in CHF thousands)

  Note   Share capital   Share premium   Accumulated losses   Total
Balance as of January 1, 2016     928   110,496   (40,381)   71,043
Net loss for the period         (7,096)   (7,096)
Other comprehensive loss         (761)   (761)
Total comprehensive loss         (7,857)   (7,857)
                   
Share-based payments 16       1,317   1,317
Preferred Series E extension shares 8   28   13,177     13,205
Proceeds from IPO net of underwriting fees 8   138   69,250     69,388
Exercise of options     41   260     301
Transaction costs 8     (5,017)     (5,017)
Balance as of December 31, 2016     1,135   188,166   (46,921)   142,380

 

      Share capital   Share premium   Accumulated losses   Total
Balance as of January 1, 2017     1,135   188,166   (46,921)   142,380
Net loss for the period         (26,411)   (26,411)
Other comprehensive loss         (780)   (780)
Total comprehensive loss         (27,191)   (27,191)
                   
Share-based payments 16       1,579   1,579
Issuance of shares:                  
 Restricted Share Awards       74   (74)  
 Exercise of options     12   59     71
Balance as of December 31, 2017     1,147   188,299   (72,607)   116,839

 

      Share capital   Share premium   Accumulated losses   Total
Balance as of January 1, 2018     1,147   188,299   (72,607)   116,839
Net loss for the period         (50,951)   (50,951)
Other comprehensive loss         (302)   (302)
Total comprehensive loss         (51,253)   (51,253)
                   
Proceeds from public offerings, net of underwriting fees 8   200   111,329     111,529
Transaction offering costs 8     (2,015)     (2,015)
Share-based payments 16           2,518   2,518
Issuance of shares:                  
 Restricted Share Awards     1   535   (535)   1
 Exercise of options     3   1     4
Balance as of December 31, 2018     1,351   298,149   (121,877)   177,623

  

The accompanying notes are an integral part of these financial statements.

 

 F-6


© AC Immune 2015